These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35192472)

  • 21. Clinical outcomes and adverse events of bariatric surgery in adults with severe obesity in Scotland: the SCOTS observational cohort study.
    Mackenzie RM; Ali A; Bruce D; Bruce J; Ford I; Greenlaw N; Grieve E; Lean M; Lindsay RS; O'Donnell J; Sattar N; Stewart S; Logue J;
    Health Technol Assess; 2024 Jan; 28(7):1-115. PubMed ID: 38343107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.
    Grabarczyk TR; Wissman NK
    Ann Pharmacother; 2020 Oct; 54(10):981-987. PubMed ID: 32274930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
    Uneda K; Kawai Y; Yamada T; Kinguchi S; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
    Sci Rep; 2021 May; 11(1):10166. PubMed ID: 33986377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of cardiorenal complications in people with type 2 diabetes and obesity.
    Drucker DJ
    Cell Metab; 2024 Feb; 36(2):338-353. PubMed ID: 38198966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Type 2 Diabetes in Frail Older Adults.
    Bahat G; Ozkok S; Petrovic M
    Drugs Aging; 2023 Sep; 40(9):751-761. PubMed ID: 37434085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity Management in Adults: A Review.
    Elmaleh-Sachs A; Schwartz JL; Bramante CT; Nicklas JM; Gudzune KA; Jay M
    JAMA; 2023 Nov; 330(20):2000-2015. PubMed ID: 38015216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea.
    Kim MK; Ko SH; Kim BY; Kang ES; Noh J; Kim SK; Park SO; Hur KY; Chon S; Moon MK; Kim NH; Kim SY; Rhee SY; Lee KW; Kim JH; Rhee EJ; Chun S; Yu SH; Kim DJ; Kwon HS; Park KS;
    Diabetes Metab J; 2019 Aug; 43(4):398-406. PubMed ID: 31441247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome.
    Bhandari M; Mathur W; Kumar R; Mishra A; Bhandari M
    Obes Surg; 2017 Dec; 27(12):3267-3272. PubMed ID: 28601988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial.
    Leslie WS; Ford I; Sattar N; Hollingsworth KG; Adamson A; Sniehotta FF; McCombie L; Brosnahan N; Ross H; Mathers JC; Peters C; Thom G; Barnes A; Kean S; McIlvenna Y; Rodrigues A; Rehackova L; Zhyzhneuskaya S; Taylor R; Lean ME
    BMC Fam Pract; 2016 Feb; 17():20. PubMed ID: 26879684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].
    García SD; Sanz SD; Sanz AD
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():14-9. PubMed ID: 24444519
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.